Procomvax

RSS

Expired

This medicine's authorisation has expired

haemophilus B conjugate (meningococcal protein conjugate) and hepatitis B (recombinant) vaccine
MedicineHumanExpired

Maltese is available via eTranslation, the European Commission's machine translation service.

Translate to Maltese | Important information about machine translation

  • Application under evaluation
  • CHMP opinion
  • European Commission decision

Overview

Sanofi Pasteur MSD S.N.C., the marketing authorisation holder (MAH) for Procomvax, has decided, for commercial reasons, not to apply for the second renewal of the marketing authorisation for this medicinal product. Consequently, the marketing authorisation for Procomvax expired on 14 May 2009. The MAH has confirmed that this decision is not related to any safety concerns. 

Procomvax (Haemophilus influenzae type b and hepatitis B vaccine) was indicated for vaccination against invasive disease caused by Haemophilus influenzae type b and against infection caused by all known subtypes of hepatitis B virus in infants six weeks to 15 months of age. It was authorised by the European Commission on 7 May 1999. 

The marketing authorisation was first renewed for five years on 14 May 2004. Alternative vaccines containing the same active substances as Procomvax are available throughout the European Union.

български (BG) (471.53 KB - PDF)

Ara

español (ES) (560.56 KB - PDF)

Ara

čeština (CS) (430.19 KB - PDF)

Ara

dansk (DA) (277.14 KB - PDF)

Ara

Deutsch (DE) (280.82 KB - PDF)

Ara

eesti (ET) (295.19 KB - PDF)

Ara

ελληνικά (EL) (455.37 KB - PDF)

Ara

français (FR) (278.01 KB - PDF)

Ara

italiano (IT) (277.41 KB - PDF)

Ara

latviešu (LV) (445.93 KB - PDF)

Ara

lietuvių (LT) (391.5 KB - PDF)

Ara

magyar (HU) (409.34 KB - PDF)

Ara

Malti (MT) (418.99 KB - PDF)

Ara

Nederlands (NL) (279.98 KB - PDF)

Ara

polski (PL) (462.1 KB - PDF)

Ara

português (PT) (280.39 KB - PDF)

Ara

română (RO) (387.58 KB - PDF)

Ara

slovenčina (SK) (414.04 KB - PDF)

Ara

slovenščina (SL) (404.36 KB - PDF)

Ara

suomi (FI) (295.82 KB - PDF)

Ara

svenska (SV) (277.19 KB - PDF)

Ara

Product information

български (BG) (944.25 KB - PDF)

Ara

español (ES) (1.08 MB - PDF)

Ara

čeština (CS) (704.2 KB - PDF)

Ara

dansk (DA) (428.1 KB - PDF)

Ara

Deutsch (DE) (424.82 KB - PDF)

Ara

eesti (ET) (465.7 KB - PDF)

Ara

ελληνικά (EL) (267.58 KB - PDF)

Ara

français (FR) (429.92 KB - PDF)

Ara

italiano (IT) (436.98 KB - PDF)

Ara

latviešu (LV) (788.42 KB - PDF)

Ara

lietuvių (LT) (468.31 KB - PDF)

Ara

magyar (HU) (672.82 KB - PDF)

Ara

Malti (MT) (729.44 KB - PDF)

Ara

Nederlands (NL) (436.53 KB - PDF)

Ara

polski (PL) (791.87 KB - PDF)

Ara

português (PT) (433.54 KB - PDF)

Ara

română (RO) (468.58 KB - PDF)

Ara

slovenčina (SK) (699.48 KB - PDF)

Ara

slovenščina (SL) (677.22 KB - PDF)

Ara

suomi (FI) (476.68 KB - PDF)

Ara

svenska (SV) (421.35 KB - PDF)

Ara
Latest procedure affecting product information:II/0028
11/12/2007
icon globe

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

 

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

español (ES) (576.22 KB - PDF)

Ara

čeština (CS) (350.49 KB - PDF)

Ara

dansk (DA) (576.59 KB - PDF)

Ara

Deutsch (DE) (327.66 KB - PDF)

Ara

eesti (ET) (323.28 KB - PDF)

Ara

ελληνικά (EL) (107.98 KB - PDF)

Ara

français (FR) (319.29 KB - PDF)

Ara

italiano (IT) (327.04 KB - PDF)

Ara

latviešu (LV) (358.41 KB - PDF)

Ara

lietuvių (LT) (342.45 KB - PDF)

Ara

magyar (HU) (349.29 KB - PDF)

Ara

Nederlands (NL) (327.77 KB - PDF)

Ara

polski (PL) (362.15 KB - PDF)

Ara

português (PT) (320.27 KB - PDF)

Ara

slovenčina (SK) (350.93 KB - PDF)

Ara

slovenščina (SL) (328.4 KB - PDF)

Ara

suomi (FI) (321.96 KB - PDF)

Ara

svenska (SV) (318.76 KB - PDF)

Ara

Product details

Name of medicine
Procomvax
Active substance
  • polyribosylribitol phosphate from Haemophilus influenzae type b as PRP-OMPC
  • outer membrane protein complex of Neisseria meningitidis (outer membrane protein complex of the B11 strain of Neisseria meningitidis subgroup B)
  • adsorbed hepatitis B surface antigen produced in recombinant yeast cells (Saccharomyces cerevisiae)
International non-proprietary name (INN) or common name
haemophilus B conjugate (meningococcal protein conjugate) and hepatitis B (recombinant) vaccine
Therapeutic area (MeSH)
  • Hepatitis B
  • Meningitis, Haemophilus
  • Immunization
Anatomical therapeutic chemical (ATC) code
J07CA

Pharmacotherapeutic group

Vaccines

Therapeutic indication

PROCOMVAX is indicated for vaccination against invasive disease caused by Haemophilus influenzae type b and against infection caused by all known subtypes of hepatitis B virus in infants 6 weeks to 15 months of age.

Authorisation details

EMA product number
EMEA/H/C/000231
Marketing authorisation holder
Sanofi Pasteur MSD, SNC

Sanofi Pasteur MSD SNC
8 rue Jonas Salk
F-69007 Lyon
FRANCE

Marketing authorisation issued
07/05/1999
Expiry of marketing authorisation
14/05/2009
Revision
9

Assessment history

español (ES) (621 KB - PDF)

Ara

čeština (CS) (386.12 KB - PDF)

Ara

dansk (DA) (263.16 KB - PDF)

Ara

Deutsch (DE) (264.2 KB - PDF)

Ara

eesti (ET) (277.53 KB - PDF)

Ara

ελληνικά (EL) (158.47 KB - PDF)

Ara

français (FR) (263.77 KB - PDF)

Ara

italiano (IT) (262.66 KB - PDF)

Ara

latviešu (LV) (426.22 KB - PDF)

Ara

lietuvių (LT) (342.86 KB - PDF)

Ara

magyar (HU) (394.28 KB - PDF)

Ara

Nederlands (NL) (266.58 KB - PDF)

Ara

polski (PL) (436.4 KB - PDF)

Ara

português (PT) (262.09 KB - PDF)

Ara

slovenčina (SK) (360.23 KB - PDF)

Ara

slovenščina (SL) (377.57 KB - PDF)

Ara

suomi (FI) (282.3 KB - PDF)

Ara

svenska (SV) (261.15 KB - PDF)

Ara

This page was last updated on

Share this page